Rakovina Therapeutics Announces Warrant Exercise Incentive Program

Core Viewpoint - Rakovina Therapeutics Inc. is implementing an early exercise warrant incentive program to encourage the exercise of up to 19,200,000 outstanding common share purchase warrants, aiming to enhance liquidity and shareholder engagement [1][3]. Summary by Sections Warrant Details - Each Eligible Warrant was originally exercisable for one common share at an exercise price of $0.20, which has been adjusted to $2.00 post a 10:1 share consolidation effective June 24, 2025 [2]. Incentive Program - The Incentive Program allows Eligible Warrant Holders to exercise their warrants at a reduced price of $0.75 per Warrant Share during a 30-day period from August 4, 2025, to September 2, 2025 [3]. - Eligible Warrant Holders can choose to exercise all, some, or none of their warrants, with no fractional Warrant Shares being issued [3]. Approval and Notification - The Incentive Program is subject to approval from the TSX Venture Exchange, and a notice will be sent to Eligible Warrant Holders detailing the program and exercise period [4]. Related Party Transaction - Jeffrey Bacha, a director and insider of the Company, is eligible to participate in the Incentive Program, which may be classified as a related party transaction under Multilateral Instrument 61-101 [5]. Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments using AI-powered drug discovery, with a pipeline of DNA-damage response inhibitors aimed at advancing drug candidates into human clinical trials [6].